Novo-Nordisk A/S (NVO) Financials
Key financial figures for Novo-Nordisk A/S (Q3 2026), as reported in DKK.
Novo raised its 2026 outlook for the third time: adjusted sales and adjusted operating profit growth are now both expected at -2% to +2% at CER, from -6% to 0%, after Q3 adjusted operating profit rose 27% at CER to DKK 31,720 million. Q3 2026 sales were DKK 79,195 million, up 6% in DKK and 4% at CER; adjusted and reported sales were the same in the quarter because no 340B provision reversal fell in Q3. Total obesity sales rose 22% at CER to DKK 26,146 million, while total diabetes sales fell 5% at CER to DKK 47,545 million. The Wegovy pill, launched in the US in January, contributed DKK 5,394 million of Q3 sales (DKK 4,178 million in US Operations, DKK 1,216 million in International Operations); Wegovy injectable was DKK 20,407 million, down 2% at CER. Ozempic was DKK 29,706 million, down 5% at CER. On the outlook: 2026 outlook raised on 4 November 2026: adjusted sales growth now -2% to +2% at CER (previously -6% to 0%) and adjusted operating profit growth now -2% to +2% at CER (previously -6% to 0%); as reported in DKK both are expected in line with CER growth. Free cash flow now DKK 60 to 70 billion (previously 45 to 55 billion), capital expenditure around DKK 50 billion (previously around 55 billion), net financial items a loss of around DKK 1.6 billion (previously 1.1 billion), effective tax rate 21% to 23% (unchanged). Figures are for Q3 2026, as Novo Nordisk A/S reported them.
- Revenue
- DKK 78.7B
- Net Income
- DKK 16.6B
- EPS
- DKK 3.74
- Total Assets
- DKK 599.2B
- Operating Cash Flow
- DKK 41.2B
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | DKK 78.7B | DKK 16.6B | DKK 3.74 | 44.92% | DKK 28.1B |
| Q2 FY2026 | DKK 78.5B | DKK 21.0B | DKK 4.74 | 34.48% | DKK 42.4B |
| Q1 FY2026 | DKK 96.8B | DKK 48.6B | DKK 10.91 | 61.57% | DKK 12.0B |
| Q4 FY2025 | DKK 79.1B | DKK 26.9B | DKK 6.04 | 40.1% | -DKK 36.2B |
| Q3 FY2025 | DKK 75.0B | DKK 20.0B | DKK 4.50 | 31.59% | DKK 30.7B |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | DKK 309.1B | DKK 102.4B | DKK 23.03 | 41.3% | DKK 29.0B |
| FY2024 | DKK 290.4B | DKK 101.0B | DKK 22.63 | 44.19% | DKK 69.7B |
| FY2023 | DKK 232.3B | DKK 83.7B | DKK 18.62 | 44.16% | DKK 70.0B |
Frequently asked questions
What was Novo Nordisk A/S's revenue last quarter?
Novo Nordisk A/S reported revenue of 78.68 billion DKK for Q3 FY2026, up 4.9% from the same period a year earlier.
Is Novo Nordisk A/S profitable?
Yes. Novo Nordisk A/S reported net income of 16.63 billion DKK for Q3 FY2026, a net margin of 21.14% on revenue.
How has Novo Nordisk A/S's margin trended?
Operating margin was 44.92% in Q3 FY2026, compared with 31.59% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Novo Nordisk A/S generate?
Novo Nordisk A/S generated free cash flow of 28.10 billion DKK in Q3 FY2026, after capital expenditure.
Figures are as reported by the filer in DKK and are not converted to US dollars. The share price is quoted in US dollars, so the two are not directly comparable.
Full income statement, balance sheet and cash flow for Novo-Nordisk A/S on SentiSense, with up to forty quarters and twenty fiscal years of history.